Healthy Skepticism Library item: 6583

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Servier claims Coversyl is “the only ACE inhibitor proven to remodel hypertensive arteries and control blood pressure throughout 24 hours after a single daily dose”
MaLAM Australian News 1995 May; 3:(5):1-2

Abstract:

In areas where there are a large number of similar products competing for a highly profitable market the companies engage in “therapeutic-class wars” to increase market share. This applies in Australia to the nine ACE inhibitors. Servier is promoting Coversyl on the basis that it remodels hypertensive arteries for 24 hours after a single dose. So far there is no clinical proof that this effect is advantageous.

Keywords:
*analysis/Australia/developed countries/Coversyl/perindopril/Servier/ ACE inhibitor/ marketing strategies/MaLAM/Medical Lobby for Appropriate Marketing/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/PROMOTIONAL STRATEGIES: INDUSTRY